Abstract
Inhibition of VEGF/Ang2 and PD-1 can enhance the tumor microenvironment to support T-cell mediated tumor cell destruction. BI 836880 is a humanized bispecific nanobody that targets VEGF and Ang2; ezabenlimab (BI 754091) is an anti-PD-1 antibody. This study determined the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of BI 836880 alone or combined with ezabenlimab in Japanese pts with solid tumors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
